Breaking: Federal Judge Grants Lilly’s Motion to Halt 340B Dispute Resolution System

In a decision that could have significant implications for 340B stakeholders, a federal district judge in Indianapolis today granted drug manufacturer Eli Lilly’s motion for a preliminary injunction stopping the U.S. Health and Human Services Department from implementing or enforcing

Read More »

Opposition to Express Scripts’ 340B Claims ID Requirement Grows

U.S. Rep. Abigail Spanberger (D-Va.) said her successful amendment today to a spending bill sends big pharma the message "Stop hiking drug prices on consumers and discriminating against our 340B providers and pharmacies."

Correction, Tuesday March 16, 4:00 p.m. EDT—Earlier today, we reported that during a March 16 webinar, advisers to 340B covered entities said that U.S. Rep. Abigail Spanberger (D-Va.) had written to pharmacy benefit manager Express Scripts (ESI) about its new

Read More »

FQHCs Fiercely Oppose Trump’s 340B Insulin Pricing Rule in New Round of Comments

HRSA received 200 comments on the Biden administration's proposal to delay until July 20 the effective date of a controversial rule on how much health centers can charge low-income patients for insulin and injectable epinephrine.

Federally qualified health centers and their trade groups are adamantly opposed to implementing a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under

Read More »

Medicare’s 340B Drug Reimbursement Cuts in 2019 Were Exacerbated by Change in Drugs’ Payment Status

A change in Medicare Part B payment status for "an unusually high" number of drugs in 2019 led to "substantially" lower payments to 340B hospitals, congressional Medicare advisers said this week.

Medicare Part B drug payments to 340B hospitals “declined substantially” in 2019 because the payment status of “an unusually high number of drugs” changed that year, congressional Medicare advisers said in a report yesterday.

The change—from “pass-through status” to “separately

Read More »

Biden Nominates Veteran Capitol Hill Aide to be HHS Assistant Secretary

Melanie Egorin, a veteran Democratic congressional health care adviser, has been tapped to be the next HHS Assistant Secretary for Legislation.

President Biden has nominated Melanie Egorin, a veteran Democratic congressional health care adviser, to serve as U.S. Health and Human Services (HHS) Assistant Secretary for Legislation.

If confirmed, Egorin would be a top deputy to Xavier Becerra, whose nomination to

Read More »

Utah Might Soon Outflank Express Scripts’ New 340B Requirement

Utah lawmakers have passed and sent to the governor a bill that would forbid insurers or their PBMs from forcing federally qualified health centers to include modifiers on claims identifying drugs as being 340B purchased, Medicaid claims excepted.

Pharmacy benefits manager Express Scripts’ (ESI) new pharmacy reporting requirement for reclassifying a previously submitted prescription drug claim as 340B-eligible “applies to the extent not prohibited by law,” the PBM says in an FAQ on its website.

ESI’s statement in

Read More »

State Activity to Rein in PBM Discrimination Against 340B Entities Heats Up

Tennessee is one of at least six states weighing legislation to forbid PBM discrimination against 340B covered entities.

At least six states have introduced or passed bills in recent weeks that would forbid pharmacy benefit managers from discriminating against 340B covered entities regarding reimbursements and other practices.

The bills range from 340B-specific legislation to broader bills to address

Read More »

Biden Wants to Delay 340B Health Center Insulin Rule Again, to July 20

Stakeholders have from today through March 14 to comment on the Biden administration's proposal to delay a controversial Trump administration about the cost of insulin at 340B health centers until July 20. | Shutterstock

The Biden administration proposes once again to push back, this time from March 22 to July 20, the effective date of the Trump administration’s controversial final rule to require health centers to provide insulin and injectable epinephrine to low-income patients

Read More »

Sanofi Calls 340B ADR System “a Faux Judicial Process”

Drug manufacturer Sanofi, in its latest filing in federal district court in New Jersey, called the new 340B administrative resolution system a false judicial process designed to punish drug companies.

Drug manufacturer Sanofi on Monday struck back at the U.S. Justice Department (DOJ) for opposing its Feb. 2 motion in a federal lawsuit requesting an injunction against the 340B program’s new administrative dispute resolution (ADR) process.

“The government is eager

Read More »

COVID Relief Bill With Implications for 340B Set to Become Law Tomorrow

The U.S. House voted 220-211 yesterday on final approval of a major COVID-19 relief bill. | C-SPAN

The U.S. House on Wednesday passed and sent to President Biden a $1.9 trillion COVID-19 relief and economic recovery bill with provisions affecting the 340B program and its participants. Biden will sign the bill at the White House tomorrow.

The

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live